Skip to main content
辰光医疗 logo

辰光医疗 - Investor Relations & Filings

Listed IPO Dec 2022
Ticker · 920300 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 390 across all filing types
Latest filing 2025-10-13 Major Shareholding Noti…
Country CN China
Listing Beijing Stock Exchange 920300

Key figures FY2024

Period ended 2024-12-31 · CNY
Headline annual figures for 辰光医疗, fiscal year 2024, reported in CNY, with the source filing for each figure.
Total Revenues CNY 119.00M per the Annual Report filed 2025-04-24
Net Income CNY -60.90M per the Annual Report filed 2025-04-24
Total Assets CNY 441.47M per the Annual Report filed 2025-04-24
Total Equity CNY 228.08M per the Annual Report filed 2025-04-24
Cash from Ops CNY -28.48M per the Annual Report filed 2025-04-24

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About 辰光医疗

http://www.shanghaicg.net/

Shanghai Chenguang Medical Technologies Co., Ltd. specializes in the research, development, and manufacturing of core components for Magnetic Resonance Imaging (MRI) systems. The product portfolio includes high-performance radiofrequency (RF) coils, superconducting magnets, and gradient coils designed for clinical, preclinical, and veterinary applications. The company focuses on high-field and ultra-high-field MRI technology, providing customized hardware solutions and integrated components to global imaging equipment manufacturers. Its technical capabilities encompass electromagnetic simulation, structural design, and precision manufacturing of specialized imaging hardware.

Recent filings

Filing Released Lang Actions
持股5%以上股东拟减持股份的预披露公告
Major Shareholding Notification Classification · 100% confidence The document is a pre-disclosure announcement regarding a shareholder holding more than 5% of shares planning to reduce their holdings. It details the shareholder's identity, shareholding percentage, planned reduction quantity, method, period, and reasons. It also includes compliance and risk disclosures related to the share reduction. This type of document is a notification about a major shareholding change, specifically a planned reduction by a significant shareholder. It does not contain financial statements or earnings data, nor is it a report or meeting material. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, confirming the classification.
2025-10-13 Chinese
投资者关系活动记录表
Call Transcript Classification · 95% confidence The document is titled as an "投资者关系活动记录表" which translates to "Investor Relations Activity Record" and is described as an "业绩说明会" or "Performance Explanation Meeting." The content consists of a Q&A session with investors discussing the company's 2025 half-year performance, product development, sales challenges, profit improvement measures, strategic transformation, and overseas business. This matches the characteristics of a Call Transcript (CT), specifically a transcript of an earnings or performance explanation meeting. The document length is 2690 characters, which is short but contains substantive Q&A content rather than just an announcement or summary. Therefore, it is not a report publication announcement or a brief summary but a transcript of an investor relations event focused on financial and operational performance.
2025-09-21 Chinese
第五届董事会第二十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 23rd meeting of the 5th Board of Directors of Shanghai Chenguang Medical Technology Co., Ltd. It details the meeting's attendance, the approval of a credit limit application, and the decision to convene an extraordinary shareholders' meeting. The content focuses on board decisions and governance matters, including voting results and conflict of interest disclosures. There is no financial report, audit, or earnings data presented. The document is not a report itself but an official announcement of board meeting resolutions, which fits the category of Board/Management Information (MANG). The document length is short (1499 characters), and it is not merely announcing the publication of a report but providing substantive board meeting decisions.
2025-09-18 Chinese
关于召开2025年第三次临时股东会通知公告（提供网络投票）
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice for convening the 2025 third extraordinary general meeting of shareholders (临时股东会通知公告) of Shanghai Chenguang Medical Technology Co., Ltd. It details the meeting date, voting methods (including online voting), agenda items, registration procedures, and proxy authorization forms. There is no financial data, earnings information, or report content. The document is an announcement informing shareholders about the meeting and how to participate, not the meeting materials or results themselves. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-09-18 Chinese
关联交易公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a related party transaction where the company plans to apply for a loan with specific terms and collateral, involving the controlling shareholder providing guarantees. It includes details about the transaction, board approvals, and legal compliance. The document is relatively short (1835 characters) and focuses on a financing-related update rather than a full financial report or earnings release. It does not contain financial statements or detailed financial analysis. Therefore, it fits best under Capital/Financing Update (CAP) as it concerns new financing arrangements and credit facilities.
2025-09-18 Chinese
国泰海通证券股份有限公司关于上海辰光医疗科技股份有限公司控股股东以及实际控制人为公司提供担保暨关联交易的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from a sponsoring institution regarding a related-party transaction where the controlling shareholder and actual controller provide guarantees for the company. It discusses the loan application, collateral, board approvals, and compliance with regulatory rules. The document is a formal verification or regulatory compliance statement related to a specific transaction, not a full financial report or earnings release. It does not contain financial statements or detailed financial data. It is also not a simple announcement of a report publication. The content fits best under Regulatory Filings (RNS) as it is a compliance and verification document related to a financing guarantee and related-party transaction.
2025-09-18 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.